Duncan Dibble and Ruth Whittington speak to Jeff Trotter about observational research and its place in the changing health technology assessment (HTA) environment. heor.tv is a collaboration between http://www.healtheconomicsdigest.com and https://www.rxcomms.com
Details
heor.tv interview Diana Brixner, former president of ISPOR and asked her how important good communications are with respect to rational decision making in the context of evidence supporting market access and reimbursement.
Details
Duncan Dibble interviewed Judith Hargreaves, Associate Director for Global Health Economics and Outcomes Research at Ethicon Products about her approach to the customer base in light of the Health Technology Assessment (HTA) landscape.
Details
heor.tv polled Mark Sculpher and Ameet Bakhai with regards to what value based pricing means to them by providing some perspective on the subject.
Details
As part of the heor.tv inteview with Jim Furniss, they asked about his thoughts on Value Based Pricing in the UK and what considerations should be mindful of before implementation in 2014.
Details
heor.tv interviewed Jim Furniss, Director of Market Access at Bridgehead International and asked what effect the global recession has had on pricing, reimbursement and market access.
Details
heor.tv ask Marjolein Pompen what the current pricing and reimbursement activities she is doing now as opposed to previously in order to keep drugs in the Dutch market.
Details
heor.tv interviewed Mark Sculpher, ISPOR president and asked; One of ISPORs Vision 2020 key goals is communication, Can you expand on what you want to improve about communication in this field?
Details
The world is a daily classroom on basic economics principles: from the Greece bailout, to the austerity measures in several EU countries, to debate over the Chinese yuan currency, to the American recession and Occupy Wall Street protests.
Details
There is a tug-of-war going on between the European Commission, with laws intended to protect the free market, and business sectors hoping to claim (or retain) exclusivity. National EU governments are using those laws to their advantage to obtain prescription drugs for the lowest prices.
Details
